A 52-WEEK PHASE 3 CLINICAL TRIAL OF RESMETIROM IN 180 PATIENTS WITH WELL-COMPENSATED NASH CIRRHOSIS

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Alkhouri, Naim [2 ]
Taub, Rebecca A. [3 ]
Neff, Guy W. [4 ]
Kowdley, Kris V. [5 ]
Noureddin, Mazen [6 ]
机构：
[1] Univ Oxford, Pinaacle Res Ctr, Oxford, England
[2] Arizona Liver Hlth, Chandler, AZ USA
[3] Madrigal Pharmaceut, Conshohocken, PA USA
[4] Covenant Metab Specialists LLC, Sarasota, FL USA
[5] Liver Care Network, Seattle, WA USA
[6] Houston Methodist Hosp, Houston, TX USA
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
100
引用
收藏
页码：S90 / S92
页数：3
相关论文
共 50 条
  • [21] Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial
    Clarke, Bart L.
    Khan, Aliya A.
    Rubin, Mishaela R.
    Schwarz, Peter
    Vokes, Tamara
    Shoback, Dolores M.
    Gagnon, Claudia
    Palermo, Andrea
    Abbott, Lisa G.
    Hofbauer, Lorenz C.
    Kohlmeier, Lynn
    Cetani, Filomena
    Pihl, Susanne
    An, Xuebei
    Smith, Alden R.
    Lai, Bryant
    Ukena, Jenny
    Sibley, Christopher T.
    Shu, Aimee D.
    Rejnmark, Lars
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [22] An Open-Label, 52-Week, Phase III Trial of Duloxetine in Japanese Patients with Chronic Low Back Pain
    Konno, Shin-ichi
    Alev, Levent
    Oda, Natsuko
    Ochiai, Toshimitsu
    Enomoto, Hiroyuki
    PAIN MEDICINE, 2019, 20 (08) : 1479 - 1488
  • [23] Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
    Merola, Joseph F.
    Sidbury, Robert
    Wollenberg, Andreas
    Chen, Zhen
    Zhang, Annie
    Shumel, Brad
    Rossi, Ana B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 495 - 497
  • [24] Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial
    Nangaku, Masaomi
    Hamano, Takayuki
    Akizawa, Tadao
    Tsubakihara, Yoshiharu
    Nagai, Reiko
    Okuda, Nobuhiko
    Kurata, Kyo
    Nagakubo, Takashi
    Jones, Nigel P.
    Endo, Yukihiro
    Cobitz, Alexander R.
    AMERICAN JOURNAL OF NEPHROLOGY, 2021, 52 (01) : 26 - 35
  • [25] A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
    Harrison, Stephen A.
    Ruane, Peter J.
    Freilich, Bradley
    Neff, Guy
    Patil, Rashmee
    Behling, Cynthia
    Hu, Chen
    Shringarpure, Reshma
    de Temple, Brittany
    Fong, Erica
    Tillman, Erik J.
    Rolph, Timothy
    Cheng, Andrew
    Yale, Kitty
    JHEP REPORTS, 2023, 5 (01)
  • [26] Clinical and immunological effects of subcutaneous methotrexate in psoriasis-First data from a 52-week phase III trial (METOP)
    Warren, Richard
    Mrowietz, Ulrich
    Frambach, Yvonne
    von Kiedrowski, Ralph
    Niesmann, Johannes
    Pfeiffer, Christiane
    Wilsmann-Theis, Dagmar
    Zschocke, Ina
    Falk, Thomas Michael
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
  • [27] Analyses of fibrosis biomarkers PRO-C3 and ELF in resmetirom treated patients from MAESTRO-NASH, a 52 Week NASH/MASH serial liver biopsy study
    Anstee, Quentin M.
    Schattenberg, Jorn M.
    Taub, Rebecca
    Labriola, Dominic
    Zhang, Hang
    Hennan, Jim
    JOURNAL OF HEPATOLOGY, 2024, 80 : S509 - S509
  • [28] Improvement in touch avoidance in patients with genital psoriasis treated with ixekizumab: 52-week results of a phase 3 clinical trial in patients with moderate-to-severe genital psoriasis (IXORA-Q)
    Soung, Jennifer
    Cather, Jennifer Clay
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB69 - AB69
  • [29] Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial
    Ailani, Jessica
    Lipton, Richard B.
    Hutchinson, Susan
    Knievel, Kerry
    Lu, Kaifeng
    Butler, Matthew
    Yu, Sung Yun
    Finnegan, Michelle
    Severt, Lawrence
    Trugman, Joel M.
    HEADACHE, 2020, 60 (01): : 141 - 152
  • [30] Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes
    Pozzilli, Paolo
    Bosi, Emanuele
    Cirkel, Deborah
    Harris, Julia
    Leech, Nicola
    Tinahones, Francisco J.
    Vantyghem, Marie-Christine
    Vlasakakis, Georgios
    Ziegler, Anette-Gabriele
    Janmohamed, Salim
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (06): : E2192 - E2206
12345